Details for Patent: 8,236,766
✉ Email this page to a colleague
Which drugs does patent 8,236,766 protect, and when does it expire?
Patent 8,236,766 protects KORSUVA and is included in one NDA.
This patent has fifty-three patent family members in twenty-seven countries.
Summary for Patent: 8,236,766
| Title: | Uses of synthetic peptide amides |
| Abstract: | The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritus and inflammation associated with a variety of diseases and conditions. |
| Inventor(s): | Claudio D. Schteingart, Frederique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo |
| Assignee: | Vifor Fresenius Medical Care Renal Pharma Ltd |
| Application Number: | US12/480,059 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,236,766 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 8,236,766
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vifor Intl | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,236,766
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2064228 | ⤷ Start Trial | 301199 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2064228 | ⤷ Start Trial | CA 2022 00045 | Denmark | ⤷ Start Trial |
| European Patent Office | 2064228 | ⤷ Start Trial | PA2022522 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2064228 | ⤷ Start Trial | LUC00282 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2064228 | ⤷ Start Trial | 2022C/546 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
